Pollak, M., Friedman, D., Barisoni, L., Falk, R., Gipson, D., Lipkowitz, M., … Chertow, G. (2022). APOL1 INHIBITION BY VX-147 AS A TARGETED THERAPY FOR APOL1-MEDIATED KIDNEY DISEASE. In AMERICAN JOURNAL OF KIDNEY DISEASES (Vol. 79, pp. 769–769).

Pollak, Martin, David Friedman, Laura Barisoni, Ronald Falk, Debbie Gipson, Michael Lipkowitz, Akinlolu Ojo, et al. “APOL1 INHIBITION BY VX-147 AS A TARGETED THERAPY FOR APOL1-MEDIATED KIDNEY DISEASE.” In AMERICAN JOURNAL OF KIDNEY DISEASES, 79:769–769, 2022.

Pollak M, Friedman D, Barisoni L, Falk R, Gipson D, Lipkowitz M, et al. APOL1 INHIBITION BY VX-147 AS A TARGETED THERAPY FOR APOL1-MEDIATED KIDNEY DISEASE. In: AMERICAN JOURNAL OF KIDNEY DISEASES. 2022. p. 769–769.

Pollak, Martin, et al. “APOL1 INHIBITION BY VX-147 AS A TARGETED THERAPY FOR APOL1-MEDIATED KIDNEY DISEASE.” AMERICAN JOURNAL OF KIDNEY DISEASES, vol. 79, no. 5, 2022, pp. 769–769.

Pollak M, Friedman D, Barisoni L, Falk R, Gipson D, Lipkowitz M, Ojo A, Chirieac M, Xu C, Fortier A, Egbuna O, Bunnage M, Chertow G. APOL1 INHIBITION BY VX-147 AS A TARGETED THERAPY FOR APOL1-MEDIATED KIDNEY DISEASE. AMERICAN JOURNAL OF KIDNEY DISEASES. 2022. p. 769–769.